XenoTherapeutics

01/06/2021

Thank you to the USPTO for granting our fourth patent, which covers how to personalize cells, tissues, and organs in the field of xenotransplantation. We are engineering tailor-made transplantable cells, enabling therapies to treat common and rare diseases. https://www.xenotherapeutics.com/patents

11/05/2020

RELEASE: Xeno-Skin, the first FDA-cleared, genetically engineered non-human organ transplant, has successfully treated our first cohort of patients suffering severe and extensive burn wounds. Very big things are coming soon. https://www.morningstar.com/news/globe-newswire/8079798/from-pig-to-patient-xenotherapeutics-completes-first-cohort-of-patients-in-first-us-clinical-trial-of-live-cell-xenotransplant-evidence-of-safety-and-efficacy-allows-for-accelerated-patient-enrollment

10/15/2020

XenoTherapeutics has been granted its first patent protecting our pathway for recovering clinical-grade cells, tissues, and organs from non-human donors for human transplantation. We are grateful to the United States Patent & Trademark Office for its speedy consideration as well as Dan Shores and Rothwell Figg IP Professionals for helping to secure this foundational IP.

Learn More 👉

Company Solidifies Patent Position Relating to FDA-Cleared Pathway for Live-Cell Transplantation Solutions

10/08/2020

https://www.facebook.com/watch/?v=769993490400340

09/11/2020

We're looking forward to hearing from esteemed xenotransplantation experts including Shinichi Matsumoto, Joseph Tector, and at . See you next week! www.tts2020.org

08/13/2020

🔥 Hot off the press: “Immunological response in cynomolgus macaques to porcine α-1,3 galactosyltransferase knockout viable skin xenotransplants—A pre-clinical study”

The results of our pre-clinical study that, in part, led to the US-FDA granted clearance to proceed with a Phase I evaluation of safety and tolerability of a vital porcine xenotransplant to provide temporary wound closure of full-thickness burn wounds. Patient enrollment for a first-in-human xenotransplantation trial commenced in 2019, at Massachusetts General Hospital, Boston, MA.

XenoTherapeutics combines fundamental principles with proven technologies in the field of xenotransplantation to provide humanized, soft tissue solutions to patients in critical need.

07/13/2020

We're excited to announce our first publication in the Journal of Xenotransplantation. A pivotal preclinical study of Xeno-Skin led the to initiate our Phase I clinical trial, and our data will be shared with the xenotransplantation community very soon.

06/11/2020

This week we're following the news :

✅ biotech is answering the call to treat COVID-19 and post-pandemic recovery
✅ bioscience will serve as an economic stabilizer
✅ our industry is continuing its resilient long-term growth

Read more: 👉

05/27/2020

Meet the Team - Part 9: Welcome back Paul Holzer, CEO of ! We look forward to having you judge again this year.

05/27/2020

We're honored to be recognized by Dr. and his colleagues working overseas on compelling xenograft material to treat burn patients. FDA clearance for our Phase I trial of Xeno-Skin is a major step forward for the global field of xenotransplantation.